Anton Pekcec

Company: Boehringer Ingelheim

Job title: Head of Diabetes & Obesity Research

Seminars:

Advancing Survodutide: Exploring the Dual Agonist’s Phase III Potential in Obesity Treatment 9:30 am

Exploring the promising Phase II results of survodutide, which demonstrated up to 19% weight loss in individuals with overweight or obesity Gain insights into the design and objectives of the upcoming global Phase III studies, focusing on the efficacy and safety of survodutide in a broader population Explore the potential of survodutide’s dual glucagon/GLP-1 receptor…Read more

day: Conference Day One